Study Evaluating SKI-606 in Subject With Solid Tumors
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of oral SKI-606 (100,
200, 300 or 400 mg) administered on a daily schedule to subjects with advanced malignant
solid tumors and to define a maximum tolerated dose (MTD) in this subject population. This
study will also obtain preliminary information on the pharmacokinetics and antitumor activity
of orally administered SKI-606 in subjects with advanced malignant solid tumors